Zentalis Pharmaceuticals Stock Income Statements

Zentalis Pharmaceuticals Quarterly Income Statements Chart

Quarterly

Annual

Operating Profit

Net Income

Zentalis Pharmaceuticals Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

license revenue			10,140,000			40,560,000
operating expenses
research and development	27,610,000	27,247,000	32,973,000	36,824,000	48,386,000	49,585,000	51,557,000	46,765,000	42,684,000	48,584,000	40,616,000	42,181,000	43,825,000	46,112,000	38,439,000	53,998,000	44,770,000	38,394,000	29,521,000	24,670,000	17,452,000	13,258,000
general and administrative	8,448,000	10,580,000	40,005,000	14,608,000	16,762,000	15,740,000	16,365,000	15,953,000	15,664,000	16,369,000	11,138,000	12,012,000	19,636,000	11,767,000	9,754,000	8,872,000	10,362,000	11,953,000	10,724,000	10,097,000	9,924,000	3,141,000
restructuring		7,796,000
total operating expenses	36,058,000	45,623,000	76,714,000	51,432,000	65,148,000	65,325,000	67,922,000	62,718,000	103,916,000	64,953,000	51,754,000	54,193,000	63,461,000	57,879,000	48,193,000	62,870,000	55,132,000	50,347,000	40,245,000	34,767,000	27,376,000	16,399,000
income from operations	-36,058,000	-45,623,000	-49,849,000	-51,432,000	-65,148,000	-24,765,000
yoy	-44.65%	84.22%
qoq	-20.97%	-8.48%	-3.08%	-21.05%	163.06%
operating margin %
other income																		-44,000
investment and other income	9,184,000	-2,656,000	2,172,000	11,247,000	-22,863,000	34,948,000	6,848,000	7,209,000	4,451,000	4,109,000	3,232,000	1,905,000	424,000	426,000	88,000	99,000	115,000		315,000	120,000	84,000
net income before income taxes	-26,874,000	-48,279,000	-47,677,000	-40,185,000	-88,011,000	10,183,000	-61,074,000	-55,509,000	-99,465,000	-60,844,000	-48,522,000	-52,288,000	-63,037,000	-57,453,000	-48,105,000	-11,189,000	-55,017,000	-50,248,000	-39,930,000	-34,647,000	-27,292,000	-16,235,000
income tax expense						143,000				108,000			17,000	33,000			45,000	196,000	426,000	18,000
net income	-26,874,000	-48,279,000	-47,472,000	-40,158,000	-88,277,000	10,040,000	-60,939,000	-55,540,000	-112,564,000	-63,262,000	-54,984,000	-54,500,000	-68,392,000	-59,237,000	-50,095,000	-10,492,000	-55,062,000	-50,444,000	-40,356,000	-34,665,000	-27,292,000	-16,235,000
yoy	-69.56%	-580.87%	-22.10%	-27.70%	-21.58%	-115.87%	10.83%	1.91%	64.59%	6.79%	9.76%	419.44%	24.21%	17.43%	24.13%	-69.73%	101.75%	210.71%
qoq	-44.34%	1.70%	18.21%	-54.51%	-979.25%	-116.48%	9.72%	-50.66%	77.93%	15.06%	0.89%	-20.31%	15.45%	18.25%	377.46%	-80.95%	9.15%	25.00%	16.42%	27.02%	68.11%
net income margin %
net income attributable to noncontrolling interests						-28,000	-22,000	-12,000	-37,000	-43,000	-13,000	-99,000	-35,000	-160,000	-36,000	-6,301,000	-488,000	-543,000	-53,000	-110,000	-435,000	-109,000
net income attributable to zentalis	-26,874,000	-48,279,000	-47,472,000	-40,158,000	-88,277,000	10,068,000	-60,917,000	-55,528,000	-112,527,000	-63,219,000	-54,971,000	-54,401,000	-68,357,000	-59,077,000	-50,059,000	-4,191,000	-54,574,000	-49,901,000	-40,303,000	-34,555,000	-26,857,000
net income per common share outstanding, basic and diluted	-370		-660	-560	-1,240		-830	-790	-1,850	-1,070	-920	-960	-1,340	-1,310	-1,130	-90	-1,340	-1,240	-980	-910	-780
common shares used in computing net income per share, basic and diluted	71,992		63	71,111	71,040		1,808	70,612	60,790	59,277	1,759	56,807	51,117	45,244	10,479.5	44,609	40,738
earnings per share
basic		-0.67				0.14
diluted		-0.67				0.14
weighted-average common shares outstanding
basic		71,678				70,898
diluted		71,678				71,192
zentera in-process research and development									45,568,000
income tax benefit			-205,000	-27,000	266,000		-135,000	31,000			-360,000	-159,000			159,000	-697,000
loss on equity method investment									13,704,000	2,310,000	6,822,000	2,371,000	5,338,000	1,751,000
operating income							-57,896,750	-62,718,000	-103,916,000	-64,953,000	-43,883,250	-54,193,000	-63,461,000	-57,879,000	-42,087,250	-62,870,000	-55,132,000	-50,347,000	-40,245,000	-34,767,000	-27,376,000	-16,399,000
income tax (benefit) expense									-605,000
gain on deconsolidation of zentera																51,582,000
interest income																		143,000				164,000
net income per class a common unit outstanding, basic and diluted																						-2,880
common shares/units used in computing net income per share/class a common unit, basic and diluted																		40,359	3,970	37,959	34,353
net income attributable to zentalis pharmaceuticals, llc																						-16,126,000
units used in computing net income per class a common unit, basic and diluted																						5,601,000

We provide you with 20 years income statements for Zentalis Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Zentalis Pharmaceuticals stock. Explore the full financial landscape of Zentalis Pharmaceuticals stock with our expertly curated income statements.

The information provided in this report about Zentalis Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.